BioAffinity Technologies Company Insiders
| BIAFW Stock | USD 0.57 0.13 18.57% |
BioAffinity Technologies employs about 75 people. The company is managed by 7 executives with a total tenure of roughly 175 years, averaging almost 25.0 years of service per executive, having 10.71 employees per reported executive. Recap of BioAffinity Technologies' management performance can provide insight into the venture performance.
BioAffinity |
BioAffinity Technologies Management Team Effectiveness
The company has return on total asset (ROA) of (0.6978) % which means that it has lost $0.6978 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5152) %, meaning that it generated substantial loss on money invested by shareholders. BioAffinity Technologies' management efficiency ratios could be used to measure how well BioAffinity Technologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.39 in 2024. Return On Capital Employed is likely to climb to -1.27 in 2024. At this time, BioAffinity Technologies' Non Current Assets Total are fairly stable compared to the past year. Total Current Assets is likely to climb to about 4 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 10 K in 2024.Common Stock Shares Outstanding is likely to drop to about 5.7 M in 2024
BioAffinity Technologies Workforce Comparison
bioAffinity Technologies Warrant is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 273. BioAffinity Technologies totals roughly 75.0 in number of employees claiming about 27% of equities under Health Care industry.
BioAffinity Technologies Profit Margins
The company has Profit Margin (PM) of (1.19) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.87) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.87.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.3 | 0.3126 |
|
|
BioAffinity Technologies Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioAffinity Technologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioAffinity Technologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, BioAffinity Technologies insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Diamond Stuart over a month ago Acquisition by Diamond Stuart of 10245 shares of BioAffinity Technologies at 1.83 subject to Rule 16b-3 | ||
Steven Girgenti over two months ago Acquisition by Steven Girgenti of 7657 shares of BioAffinity Technologies at 4.2 subject to Rule 16b-3 | ||
Zannes Maria over two months ago Disposition of tradable shares by Zannes Maria of BioAffinity Technologies subject to Rule 16b-3 | ||
Knight Peter S over two months ago Disposition of 7142 shares by Knight Peter S of BioAffinity Technologies at 4.2 subject to Rule 16b-3 | ||
Meghji Mohsin Y over six months ago Acquisition by Meghji Mohsin Y of 9920 shares of BioAffinity Technologies at 1.89 subject to Rule 16b-3 | ||
Dougherty Michael Philip over six months ago Insider Trading | ||
Steven Girgenti over six months ago Acquisition by Steven Girgenti of 156602 shares of BioAffinity Technologies at 4.2 subject to Rule 16b-3 |
BioAffinity Technologies Notable Stakeholders
A BioAffinity Technologies stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BioAffinity Technologies often face trade-offs trying to please all of them. BioAffinity Technologies' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BioAffinity Technologies' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Steven Girgenti | Founder Board | Profile | |
| Julie Overton | Director Communications | Profile | |
| Timothy JD | Secretary VP | Profile | |
| Dallas Coleman | National Sales | Profile | |
| William Bauta | Senior Therapeutics | Profile | |
| Maria JD | President, Founder | Profile | |
| Xavier MS | VP Operations | Profile |
About BioAffinity Technologies Management Performance
The success or failure of an entity such as BioAffinity Technologies often depends on how effective the management is. BioAffinity Technologies management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioAffinity management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioAffinity management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.33) | (1.39) | |
| Return On Capital Employed | (1.33) | (1.27) | |
| Return On Assets | (0.97) | (1.01) | |
| Return On Equity | (1.63) | (1.55) |
Please note, the imprecision that can be found in BioAffinity Technologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of bioAffinity Technologies Warrant. Check BioAffinity Technologies' Beneish M Score to see the likelihood of BioAffinity Technologies' management manipulating its earnings.
BioAffinity Technologies Workforce Analysis
Traditionally, organizations such as BioAffinity Technologies use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BioAffinity Technologies within its industry.BioAffinity Technologies Manpower Efficiency
Return on BioAffinity Technologies Manpower
| Revenue Per Employee | 33.8K | |
| Revenue Per Executive | 361.8K | |
| Net Loss Per Employee | 105.8K | |
| Net Loss Per Executive | 1.1M | |
| Working Capital Per Employee | 23K | |
| Working Capital Per Executive | 246.4K |
Additional Tools for BioAffinity Stock Analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.